Related Experiment Video
Updated: Jun 16, 2026
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer
Keiichiro Tada1, Akiko Ogiya, Kiyomi Kimura
1Department of Breast Surgery, Cancer Institute Hospital, Tokyo, Japan. ktada@jfcr.or.jp
Background:
The impact of sentinel lymph node biopsy on breast cancer mimicking ductal carcinoma in situ (DCIS) is a matter of debate.
Methods:
We studied the rate of occurrence of sentinel lymph node metastasis in 255 breast cancer patients with pure DCIS showing no invasive components on routine pathological examination. We compared this to the rate of occurrence in 177 patients with predominant intraductal-component (IDC) breast cancers containing invasive foci equal to or less than 0.5 cm in size.
Results:
Most of the clinical and pathological baseline characteristics were the same between the two groups. However, peritumoral lymphatic permeation occurred less often in the pure DCIS group than in the IDC-predominant invasive-lesion group (1.2% vs. 6.8%, p = 0.002). One patient (0.39%) with pure DCIS had two sentinel lymph nodes positive for metastasis. This rate was significantly lower than that in patients with IDC-predominant invasive lesions (6.2%; p < 0.001).
Conclusions:
Because the rate of sentinel lymph node metastasis in pure DCIS is very low, sentinel lymph node biopsy can safely be omitted.
